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ABSTRACT
Introduction: Hypoglycemia is a common side
effect of insulin therapy and has negative
implications for quality of life and healthcare
resources. The authors investigated the self-
reported frequency of non-severe and severe
hypoglycemic events (NSHEs and SHEs),
hypoglycemia awareness, patient–physician
communication, health-related effects and
economic impact on people with insulin-
treated diabetes (Type-1 and Type-2) in Spain.
Methods: People with Type-1 (T1DM) or
insulin-treated Type-2 (T2DM) diabetes older
than 15 years of age completed up to 4
questionnaires at weekly intervals. NSHE was
an event which respondents could manage
without assistance. SHE needed help from a
third party to manage.
Results: In total, 630 respondents completed
questionnaires covering 2,235 weeks. Mean self-
reported NSHEs per respondent-week were 1.7
(T1DM) and 0.4–0.8 (T2DM). Impaired
hypoglycemia awareness or unawareness was
reported by 55% of T1DM and 39% of T2DM
respondents. Overall, 31% of T1DM and 20% of
T2DM respondents rarely/never informed their
physician about NSHEs. Respondents reported
feeling tired/fatigued after 67% of NSHE and
less alert after 45% of NSHE. Over the week
following an NSHE, blood glucose measurement
test-strip use increased by 5.3 (mean). In
employed respondents (43%), 18% of NSHEs
were reported to lead to lost work time (mean
1.5 h per event). After an SHE, 49% of
respondents required emergency visits and/or
hospital admission.
Conclusion: NSHE are a common occurrence
with T1DM and insulin-treated T2DM in Spain
and are associated withacost burdenand negative
impact on well-being. Patient–physician
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communication is higher in Spain than Europe
overall; however, many patients expressed
reluctance to discuss their hypoglycemia.
Keywords: Diabetes; Economic impact;
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INTRODUCTION
The prevalence of diabetes is increasing and
according to the International Diabetes
Federation (IDF), more than 3.8 million adult
citizens currently live with diabetes in Spain,
corresponding to a prevalence of 10.8% (2013
estimate) [1]. Other studies have estimated a
slightly higher prevalence of diabetes (B15%)
[2], the most recent reporting a prevalence of
13.8% in a representative sample of the Spanish
population [3].
Maintenance of normoglycemia, often
through the use of insulin, is the cornerstone
of optimal diabetes management. However,
intensification of insulin therapy can lead to
an increased incidence of hypoglycemia: the
most common adverse event associated with
insulin treatment [4]. Hypoglycemic episodes
are defined as either severe or non-severe
depending on whether assistance is required
by another individual, or whether the person
can manage the event alone, respectively [5, 6].
Non-severe hypoglycemic events (NSHEs)
account for 88–98% of all events [7–9] and
have been shown to impact the health-related
quality of life of people with diabetes [7, 10].
Furthermore, the rise in the prevalence of
diabetes may also create problems for
healthcare systems as hypoglycemia can have
a direct and indirect economic impact [11].
Hypoglycemia also represents a barrier to
optimal diabetes management, as fear of
hypoglycemic events can cause sub-optimal
insulin therapy and poor glycemic control [12,
13]. Although international diabetes bodies (the
European Association for the Study of Diabetes
and the American Diabetes Association)
highlight that education on the recognition
and treatment of hypoglycemia is an important
part of diabetes management, the real-world
level of patient–physician communication
regarding hypoglycemia is not known [14].
There are limited data on the frequency of
hypoglycemia outside of clinical trial settings
and, furthermore, there are few studies
reporting data for NSHEs in people with Type
1 Diabetes Mellitus (T1DM) and Type 2 Diabetes
Mellitus (T2DM) in Spain. Previous European
studies have reported real-world estimates
[8–10, 15]; however, results vary according to
the definition of events used, methods of data
collection, and country coverage. Moreover,
limited data exist on the health-related impact
and the use of healthcare resources due to
NSHEs in Spain.
This paper reports the frequency of self-
reported NSHEs and severe hypoglycemic
events (SHEs) in people with T1DM and
insulin-treated T2DM in Spain. Additionally,
levels of impaired hypoglycemia awareness,
patient–physician communication of
hypoglycemic events and the health-related




A full description of the methodology for this
study has been previously reported by O¨stenson
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et al. [16]. Respondents in Spain were recruited
using existing large consumer panels that
provided a representative sample of the
general diabetes population. People over the
age of 15 with a T1DM or T2DM diagnosis,
receiving insulin, were included in the survey.
Respondents with T2DM were divided into
three subgroups based on regimen: long acting
insulin only (basal only therapy; T2BOT), short
and long acting insulin (basal bolus; T2BB) or
other insulin regimens (e.g., premix; T2O).
A small incentive (5€) was offered for
completion of the questionnaire, in line with
current market research guidelines and to
ensure that there was no undue incentive to
participate. Questionnaires were completed
anonymously in accordance with the
regulations and practice of market research
governing bodies European Society for
Opinion and Marketing Research (ESOMAR)
[17] and European Pharmaceutical Market
Research Association (EphMRA) [18].
Materials: Online Questionnaires
Four waves of questionnaires were sent out over
4 weeks. The first questionnaire collected
information on respondent demographics and
patient awareness of hypoglycemia. It also
collected the self-reported number of NSHEs in
the preceding seven days and the number of
SHEs in the past year. The subsequent three
questionnaires recorded the frequency of NSHEs
in the preceding seven days only. Data on the
impact of hypoglycemia (particularly NSHE;
based on a respondent’s last NSHE within the
7-day recall period) on respondent well-being,
work productivity and healthcare resource use
were also collected. The questionnaire was
based on one used in a previous study, [19]
which was created using insights collected
during focus groups on the self-reported
impacts of hypoglycemia [20]. Adaptations
made to the questionnaire for this study
included questions on frequency.
Definitions and Calculations
An NSHE was defined as symptoms of
hypoglycemia (e.g., sweating, shaking, and
headache) with or without a blood glucose
measurement, or a low blood glucose
measurement (B3.1 mmol/L) without
symptoms, that the individual managed
without assistance. An SHE was defined as an
event of low blood glucose level (B3.1 mmol/L)
needing help from a third party to manage (e.g.,
help from a family member or a health care
professional, including emergency room visits
and hospitalization).
Weekly NSHE frequencies were calculated
using data from all respondents completing at
least one questionnaire (wave) with annual
frequency calculated using the mean weekly
event frequency multiplied by 52. Standard
descriptive methods (means/percentage and
standard deviations) were used to report
results for respondents.
The classification system for awareness of
hypoglycemia was based on a prospectively
validated study by Pedersen-Bjergaard et al.
[21]. Any respondent who answered
‘sometimes’ or ‘never’ to the question ‘‘can
you feel when your blood sugar is low?’’ was
assigned as being unaware of hypoglycemia,
those who answered ‘usually’ as having
impaired awareness and those who answered
‘always’ deemed to be aware. Comparisons of
NSHE frequencies according to respondent
awareness were performed using t tests with an
employed significance level of p\0.05.
This was a non-interventional market research
study. Questionnaires were completed
anonymously in accordance with the
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regulations and practice of market research
governing bodies: European Society for Opinion
and Marketing Research (ESOMAR) and
European Pharmaceutical Market Research
Association (EphMRA). The EphMRA Code of
Conduct states that Market Research does not
require Clinical Research Ethics Committee or
Independent Review Board approval.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Informed consent was obtained from all
patients for being included in the study.
RESULTS
Subjects
The 630 patients entering the study completed
in total 2,235 patient-week records with 90, 85
and 80% completing wave two (570 patients),
wave three (534 patients) and wave four (506
patients), respectively. The frequency of NSHEs
is based on 2,235 respondent-week records.
Demographics for respondents are shown in
Table 1. In total, 47% of respondents had T1DM
and 53% of respondents had T2DM.
Frequency of NSHEs
The mean self-reported NSHEs per week were
1.7 for T1DM, 0.4 for T2BOT, 0.8 for T2BB and
0.6 for T2O respondents. Annual calculated
NSHE frequencies were 88.0, 18.3, 42.1 and
29.8 for T1DM, T2BOT, T2BB and T2O,
respectively. The proportion of NSHE
occurring at night was 26% in T1DM and
30–32% in T2DM respondents (depending on
insulin treatment).
Self-reported mean annual SHE frequencies
were 0.9 for T1DM, 0.3 for T2BOT, 0.3 for T2BB
and 0.4 for T2O respondents.
Self-Reported Hypoglycemia Awareness
and Corresponding NSHE/SHE Frequency
In T1DM respondents who had previously
experienced an NSHE (i.e., at any point in
the past, and not just in the study recall
period), 42% reported an impaired awareness
of hypoglycemia. Impaired awareness was
reported by 25% of T2DM respondents
(Table 2). A further 13% of T1DM and 14%
of T2DM respondents were classified as
unaware.
Respondents with T2DM who had impaired
awareness of hypoglycemia had a significantly
(p\0.05) higher NSHE frequency than those
who were aware, driven by a significant
difference in T2BOT respondents. A similar
trend (although not significant) was seen in
T2BB and T1DM respondents.
T2DM respondents with impaired awareness
reported a significantly (p\0.05) higher SHE
frequency compared with respondents who




Overall, 31% of T1DM and 20% of T2DM
respondents rarely or never informed their
general practitioner (GP)/specialist about
NSHEs (Table 3). The frequency of NSHE was
significantly lower in T2BOT and T2BB
respondents who rarely/never inform their GP/
specialist about NSHEs. An opposing trend was
seen in T1DM and T2O respondents, where the
frequency of NSHEs was higher in respondents
who rarely/never inform their GP/specialist,
although this trend was not statistically
significant (Table 3).
When respondents were asked about topics
discussed during GP/specialist consultations,
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10% of T1DM and 13% of T2DMrespondents
reported that their GP/specialist did not ask
about hypoglycemia during routine
appointments (Table 3).
Economic Impact of NSHEs
NSHE resulted in increased use of healthcare
resources (Table 4). Over the seven days
following an NSHE, blood glucose
measurement (BGM) test-strip use increased by
a mean of 5.0 in T1DM and 5.9 in T2DM
respondents. This equates to an estimated
additional resource use of €1.3/event (cost/test-
strip €0.25) [22, 23]. In respondents with T1DM,
8% of daytime and 12% of nocturnal NSHE
during the study period led respondents to
contact a healthcare professional (HCP)
(Table 4). A fifth of NSHE (20%) in
respondents with T2DM resulted in contact
with a HCP, regardless of the time of day that
the event occurred.
Among respondents who had experienced an
SHE, 30% required emergency hospital visits
following their last SHE and 19% were admitted
to hospital. In employed T1DM respondents
(n = 185), 18% of NSHE led to lost work time
with approximately 1.5 h work time lost per
event. In employed T2DM respondents (n = 89),
15% of NSHE led to lost work time, with
approximately 1 h’ work time lost per event
(Table 4).
Table 1 Respondent demographics
Type 1 Type 2
Number of respondents,
n (%)
294 (47%) 336 (53%)
Age, mean (SD) 39.9 (12.8) 63.5 (15.1)
Gender, female, n (%) 143 (49%) 150 (45%)
Marital status, n (%)
Single 102 (35%) 79 (24%)
Married 145 (49%) 239 (71%)
Partner 47 (16%) 18 (5%)
Living arrangements, n (%)
Alone 21 (7%) 33 (10%)
With others 273 (93%) 303 (90%)
Employed, n (%) 185 (63%) 89 (26%)
Education, n (%)
Primary school 32 (11%) 165 (49%)
High school 132 (45%) 85 (25%)
University
(plus PhD or higher)
129 (44%) 75 (22%)
Other 1 (0%) 11 (3%)
BMI, mean (SD) 25.5 (5.1) 29.0 (5.9)
Smoking, n (%)
Smoker 111 (38%) 61 (18%)
Ex-smoker 57 (19%) 135 (40%)
Non-smoker 126 (43%) 140 (42%)
Diabetes duration, n (%)
Average in years (SD) 18.5 (11.0) 20.0 (16.4)
\2 years 2 (1%) 5 (1%)
2–5 years 31 (11%) 45 (13%)
5–9 years 31 (11%) 43 (13%)
10–14 years 50 (17%) 67 (20%)
C15 years 180 (61%) 176 (52%)
Insulin treatment type, n (%)
Long acting insulin only 30 (10%) 179 (53%)
Both short and long
acting insulin
211 (72%) 95 (28%)
Other insulin types 53 (18%) 62 (18%)
Duration of insulin
treatment, n (%)
Average in years (SD) 16.5 (10.5) 8.0 (8.3)
\2 years 7 (2%) 62 (18%)
2–5 years 44 (15%) 114 (34%)
5–9 years 26 (9%) 54 (16%)
C10 years 217 (74%) 106 (32%)
Mean HbA1c
Mean mmol/mol (SD); 61.6 (18.8) 78.8 (29.7)
NGSP %, (SD) 7.8 (1.7) 9.4 (2.7)
Table 1 continued
Type 1 Type 2
Medical complicationsa, none reported, n (%) 186 (63%) 157 (47%)
BMI body mass index, HbA1c hemoglobin A1c (glycosylated
hemoglobin), NGSP National Glycohemoglobin Standardization
Programme, SD standard deviation
a Questionnaire options for medical complications included: none, eye
problems, neuropathy, cardiovascular disease, renal disease, amputations,
other (please specify)
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Patient Impact of NSHEs
Respondents reported negative health-related
impacts following their last NSHE, including
feeling tired/fatigued (following 70% and 63%
of NSHE in T1DM and T2DM, respectively),
less alert (48% and 42% of NSHE in T1DM
and T2DM) and ill/uncomfortable (39% and
47% of NSHE in T1DM and T2DM).
Respondents’ emotional well-being was also
affected, with NSHE resulting in feeling
emotionally low (following 37% and 35% of
NSHE in T1DM and T2DM, respectively),
anxious/nervous (31% and 38% in T1DM
and T2DM) and moody (30% and 26% in
T1DM and T2DM).
Figure 1 shows the reported impact of NSHEs
on daily routine for all respondents combined
(i.e., T1DM and T2DM), according to if they
were day or nighttime events. The specific
impact of NSHEs relating to daily routine was
similar, regardless of the time of day they
occurred.
These overall findings were reflected in the
specific results for respondents with T1DM or
T2DM. T1DM respondents reported having less
energy than usual following 57% of daytime
NSHE and 50% of nighttime NSHE, having a
Table 2 Self-reported respondent awareness of hypoglycemia and corresponding frequency of NSHEs and SHEs
All respondents who have previously












Can you feel when your blood sugar is low? % (n)
Always aware 45% (121) 61% (150) 61% (70) 53% (44) 73% (36)
Impaired awareness 42% (114) 25% (62) 23% (26) 35% (29) 14% (7)
Unaware 13% (36) 14% (34) 16% (18) 12% (10) 12% (6)
NSHE frequency per week stratiﬁed by respondents’ awareness, mean (SD)
Always aware 1.75 (2.43) 0.53 (1.42) 0.37 (1.08) 0.79 (2.05) 0.54 (0.95)
Impaired awareness 1.88 (2.42) 0.91 (1.81)* 0.78 (1.64)* 1.16 (2.08) 0.36 (0.58)
Unaware 1.63 (2.24) 0.77 (1.99) 0.47 (1.41) 0.62 (1.04) 2.00 (3.74)
SHE frequency in the past year stratiﬁed by respondents’ awareness, mean (SD)
Always aware 0.91 (2.71) 0.23 (1.31) 0.33 (1.86) 0.16 (0.53) 0.11 (0.40)
Impaired awareness 1.04 (3.20) 0.61 (1.25)* 0.65 (1.70) 0.62 (0.82)* 0.43 (0.79)
Unaware 1.31 (3.39) 0.79 (2.53) 0.39 (1.20) 0.20 (0.63) 3.00 (5.44)
NSHE non-severe hypoglycemic event, SD standard deviation, SHE severe hypoglycemic event, T1DM type 1 diabetes
mellitus, T2BB type 2 diabetes mellitus respondents receiving basal bolus therapy/short and long acting insulin, T2BOT type
2 diabetes mellitus respondents receiving basal only therapy/long acting insulin only, T2DM type 2 diabetes mellitus, T20
type 2 diabetes mellitus respondents receiving other therapy (e.g., mixed insulin)
* Signiﬁcant change versus always aware group or always/usually group (comparisons performed using t tests with an
employed signiﬁcance level of p\0.05); however, the analysis of T2DM subgroups (T2BOT, T2BB, T2O) is inconclusive
due to the small number of respondents who had impaired awareness in each group
a Base: All respondents that have previously experienced an NSHE at any point (not just in study recall period)
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headache following 32% (daytime) and 30%
(nighttime) of NSHE, and requiring daytime
sleeping following 35% (daytime) and 32%
(nighttime) of NSHE. T2DM respondents
reported similar trends with 54% of daytime
and 43% of nighttime NSHE resulting in
reduced energy levels, 27% (daytime) and 24%
(nighttime) of NSHE resulting in headaches,
and 36% (daytime) and 30% (nighttime) of
NSHE leading to daytime sleeping. Respondents
also changed their behavior relating to insulin
administration, reducing their normal insulin
dose following 25% (T1DM) and 20% of NSHE
(T2DM).
DISCUSSION
This study identifies the real-world frequency
of NSHEs and SHEs both in people with T1DM
and people with insulin-treated T2DM in
Spain. Furthermore, it provides an insight
into the negative impact of NSHEs on patient
well-being and healthcare resource use specific
to Spain.












All respondents who have previously experienced an NSHEa (n = 517)
Proportion of respondents who rarely/never
inform their GP/specialist about NSHEs, % (n)
31% (85) 20% (50) 22% (25) 19% (16) 18% (9)
Number of NSHE in those respondents
communicating versus those who do
not tell their GP specialist
Always/usually 1.69 (2.15) 0.77 (1.44) 0.57 (1.13) 1.00 (1.62) 0.81 (1.67)











Based on all respondents completing
wave 1 (n = 630)b
GP/specialist did not ask about
hypoglycemia during
routine appointments
10% 15% 16% 15% 13%
NSHE non-severe hypoglycemic event, T1DM type 1 diabetes mellitus, T2BB type 2 diabetes mellitus respondents receiving
basal bolus therapy/short and long acting insulin, T2BOT type 2 diabetes mellitus respondents receiving basal only therapy/
long acting insulin only, T2DM type 2 diabetes mellitus, T20 type 2 diabetes mellitus respondents receiving other therapy
(e.g., mixed insulin)
* Signiﬁcant change versus always aware group or always/usually group (comparisons performed using t tests with an
employed signiﬁcance level of p\0.05); however, the analysis of T2DM subgroups (T2BOT, T2BB, T2O) may be
inconclusive due to the small number of respondents who rarely/never inform their GP/specialist about NSHEs
a Base: All respondents that have previously experienced an NSHE at any point (not just in study recall period) (n = 517)
b Base: All respondents completing wave 1 (n = 630)
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Frequency of Hypoglycemic Events
The self-reported frequencies of NSHEs and
SHEs in Spain are similar to those seen in the
overall European study using the same
methodology, across all respondent subgroups
[16]. In comparison to other previously
conducted European studies, the frequency of
NSHEs was similar for T1DM (1.7 in this study
versus 1.8–2.2 in previous studies [9, 24, 25]),
but differed for T2DM (0.4–0.8 in this study
versus 0.3 in a previous study in Scotland [8]).
This variation may be due to differences in the
geographical region, T2DM treatment regimen,
and study sample size, or how hypoglycemic
events had been defined [8]. For example, the
study in Scotland was substantially smaller (less
than half the size of the Spanish study), with at
least 70% of respondents with T2DM receiving
premixed insulin (compared to fewer than 10%
in this study). In addition, the definition of
NSHE in the study in Scotland is narrower—all
symptomatic NSHEs were recorded with a BGM,
whereas this study included the detection of
hypoglycemic symptoms with or without
confirmation through a BGM [8].
The frequency of NSHE in T1DM
respondents in this study is double the
frequency of NSHE in T2DM respondents. It
has been suggested that the risk of
hypoglycemia in people with insulin-treated
T2DM increases with longer diabetes duration,
[8] and Henderson et al. [26] reported that
NSHE frequency among people with T2DM only
reached the same level as in people with T1DM
after 10 years of insulin use in T2DM [26]. In the
present study, only 32% of respondents with
T2DM had received insulin for over 10 years,
Table 4 Economic impact of hypoglycemic events
T1DM T2DM T2BOT T2BB T2O
Last NSHE across all respondents
Percentage of daytime NSHE resulting in contact with HCPa 8% 20% 17% 20% 28%
Percentage of nocturnal NSHE resulting in contact with HCPb 12% 20% 30% 11% 22%
Mean increase BGM in the week following an NSHEc
Overall 5.0 5.9 6.0 7.1 4.1
Daytime NSHE 4.5 5.5 5.1 7.1 4.1
Nighttime NSHE 6.5 7.0 10.3 6.9 4.1
Respondents experiencing SHE (n = 235)
Percentage of respondents reporting an SHE who required emergency
hospital visits
30% 30% 28% 23% 46%
NSHE from employed respondents (n = 569)
Percentage of NSHE reported to lead to lost work time 18% 15% 12% 18% 9%
Average working time lost after NSHE (min) 90.4 64.1 159.5 28.8 67.5
HCP healthcare professional,Mins minutes, NSHE non-severe hypoglycemic event, SHE severe hypoglycemic event, T1DM
Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus
a Base: Last daytime NSHE across all respondents (n = 838)
b Base: Last nocturnal NSHE across all respondents (n = 240)
c Base: Last NSHE across all respondents (n = 993)
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which may partly explain the lower frequency
of NSHEs. In T2DM, the frequency of NSHE also
varies according to treatment regimen,
although this is expected due to the different
types of insulin coverage [14].
Self-Reported Hypoglycemia Awareness
and Implications for SHEs
In the present study, the authors investigated
levels of hypoglycemia awareness in Spain.
Reports of unawareness were similar between
T1DM (13%) and T2DM (14%) respondents,
although impaired awareness was higher in
T1DM respondents (42% versus 25%). This is
consistent with the overall European findings
[16]. Consideration should be given to
respondent demographics when comparing
awareness levels across respondent groups. For
example, the prevalence of impaired awareness
is reported to increase with diabetes duration in
T1DM, [9] which may confound the results of
this study. Further investigation with larger
sample sizes is required to fully understand the
complex relationship between diabetes
duration, hypoglycemia awareness and NSHE
frequency.
Impaired awareness has previously been
reported as the most important risk factor for
severe hypoglycemia [27]. The results of this study
support this finding; T2DM respondents with
impaired awareness reported significantly higher
SHE frequencies (p\0.05) than respondents who
were aware of their hypoglycemia. This trend,
Fig. 1 The patient-reported impact of daytime and night-
time non-severe hypoglycemic events in Type 1 Diabetes
Mellitus and Type 2 Diabetes Mellitus patients combined.
Base: All last events from respondents with at least one last
event being a daytime (n = 342)/nighttime (n = 91) event
in one of the waves. N/A not applicable, NSHE non-severe
hypoglycemic event
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although not significant, was also seen for T1DM
respondents. The statistical analysis of T2DM
subgroups (T2BOT, T2BB, and T2O) may be
inconclusive due to the small number of
respondents with impaired awareness in each
group. Further investigation with larger sample
sizes is required to fully understand the trends for
people receiving different insulin regimens.
Patient–Physician Communication
Regarding Hypoglycemia
and Corresponding NSHE Frequency
An interesting finding of this study is the higher
patient–physician communication levels
observed in Spain, compared to the overall
European study [16]. The proportion of
Spanish respondents who always/mostly
inform their GP/specialist of a hypoglycemic
event was nearly double that observed in the
wider European study [16] (approximately
70–80% in Spain versus 35–50% in Europe).
Furthermore, only a small proportion of
respondents stated that their GP/specialist did
not ask about hypoglycemia (10–16% in Spain,
compared to 17–28% in Europe).
This study also analyzed trends in NSHE
frequency according to patient communication
of hypoglycemia. T2DM respondents who
always/usually inform their GP/specialist about
their hypoglycemia reported significantly
(p\0.05) higher NSHE frequencies than those
who rarely/never inform their GP/specialist.
Although causality cannot be established,
these results suggest that patients who
experience hypoglycemia more often are more
likely to discuss their events with their
physician (potentially in an attempt to
improve their recognition and treatment of
hypoglycemia; although this was not
investigated as part of this study). Despite this,
almost a third of patients surveyed in Spain
expressed reluctance to discuss their
hypoglycemia, which may be due to wider
factors such as concerns regarding driving
privileges, [12] implications for employment,
or fear that they may be perceived by their
general practitioner/specialist to have poor
control of their diabetes. Further research is
needed to understand the reasoning behind
why people may not actively be reporting their
hypoglycemic events.
Patient-burden and Economic Impact
of NSHEs
Unsurprisingly, NSHEs were shown to have a
negative effect on respondent’s physical and
emotional well-being. The impact following a
nighttime or a daytime NSHE was relatively
similar across diabetes type. NSHE also altered a
patient’s daily routine, as a quarter of T1DM
and a fifth of T2DM reduced their normal
insulin dose following an NSHE. This is
consistent with an average of 24.9% reported
in a study by Brod et al. [19] in a study of 4
countries (USA, UK, Germany and France).
Respondents may have altered their correct
insulin dose following an NSHE in fear of a
future hypoglycemic event, an avoidance
behavior shown to be a substantial obstacle to
appropriate diabetes management [28–30].
Another adaptive behavior demonstrated by
diabetes patients, in this study and previous
studies, is an increase in self-monitoring of
glucose levels. Whilst this change in diabetes
self-management behavior is an appropriate
adaptive response which may help prevent
new events in the short-term [12], it presents a
direct cost burden through increased healthcare
resource use (i.e., increase in BGM test-strip
consumption). This burden could be alleviated
if NSHE frequency was reduced through
improved awareness and recognition of events.
164 Diabetes Ther (2014) 5:155–168
The increase in BGM test-strip use in the week
following an NSHE in this study (5.0–5.9) is
comparable to that reported by Brod et al. in a
study of 4 countries (5.6) [19]. The increase in
BGMs following nighttime NSHEs in this study
(6.5 in T1DM and 7.0 in T2DM) was similar to
that reported by Spanish respondents in a study
focusing on nighttime NSHE (6.8) [31]. An
additional contributor to the direct cost
burden of NSHEs in Spain is the resulting
contact with HCPs.
Although direct costs associated with SHE are
not reported in this study, the cost of an SHE to
the Spanish healthcare system has previously
been reported as €3,500 per event [11]. On
average, 30% of respondents reported an
emergency hospital visit following an SHE in
this study, and 19% were admitted to hospital
(16% T1, 25% T2). Considering the higher
frequency of SHE reported in Spain compared
to the European study, this could present a
substantial burden on the Spanish healthcare
system.
NSHE and SHE also present an indirect cost
burden in Spain through lost work time. The
percentage of NSHE reported to lead to lost
work time in this study (18%) is the same as that
reported by Brod et al. [19]. However, the
amount of work time lost due to an NSHE was
considerably lower in this study (1.5 h)
compared to Brod et al. (9.9 h). This could be
explained by this study encompassing NSHE
which occurred outside work time, whereas
Brod et al. [19] included only NSHE which
occurred during working hours.
Comparison to Methodologies used
in Other Publications
Methodological differences between this study
and the UK Hypoglycemia Study Group study
[15] relate to the recall period, patient
subgroups, and the classification of
hypoglycemia awareness. Patients in the UK
Hypoglycemia Study recorded each
hypoglycemic event as it occurred for
9–12 months [15], whereas this study used a
7-day recall period over 4 weeks. The recall
period chosen for this study was supported by
a previous study demonstrating that a
respondent’s ability to remember NSHE during
the previous week was not significantly
different from the prospective recording of
events over 1 week [9]. Another study has
shown that people with T1DM and people
with T2DM are able to accurately recall severe
hypoglycemic events within a 1-year period
(corresponding with the recall period in the
current study) [21]. In addition to collecting
self-reported data, the UK Hypoglycemia Study
recorded biochemical hypoglycemia through
continuous glucose monitoring with a
continuous glucose monitoring system
(CGMS) [15]. Patient subgroups also varied—
the UK study compared the frequency of
hypoglycemic events on the basis of recent or
prolonged duration of insulin therapy, plus use
of sulfonylureas without insulin in T2DM
respondents [15]. Finally, in the UK
Hypoglycemia Study, patients rated their
awareness of hypoglycemia symptoms on a
scale from 1 to 7 (1 = full awareness, 7 = total
unawareness) [15]. This study used three
categories (unaware, impaired awareness,
always aware), thereby enabling identification
of the gradual loss of awareness, in contrast to
the Clarke [32] and Gold [33] methods which
use only two categories (aware/unaware).
Whilst there is no consensus on how to
classify awareness, the method used in this
study is the only one proven to perform
similarly across language barriers [34].
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Study Limitations
The limitations of the study have been reported
previously, by O¨stenson et al. [16]. A total of
10% of respondents with T1DM in Spain
reported receiving long acting insulin only.
Since long acting insulin as monotherapy
should only be used in T2DM, this may
indicate that some respondents with T2DM
had incorrectly reported their condition as
T1DM. If this is the case, the proposed study
may underestimate the frequency of events in
T1DM, since the respondents reported as
having T2DM had fewer hypoglycemic events.
There is also the potential that the study
duration may over- or underestimate the annual
frequency of hypoglycemia, as seasonal
variation is not considered (study conducted
December to May). Self-reporting and
anonymity also make validation of patient
data impossible, and as the response rates for
waves of the study diminished (90%, 84% and
80% of respondents completed wave two, three
and four, respectively), the authors cannot rule
out the possibility that later waves were
completed by respondents who had more
experience of hypoglycemic events.
CONCLUSION
This study shows that NSHEs are a common
occurrence across people with T1DM and T2DM
in Spain. Although communication levels
between respondents and GP/specialists are
higher than reported across Europe as a whole,
respondents experience a similar frequency of
NSHEs, demonstrating a need for patient
education surrounding hypoglycemia
management. The importance of improving
glycemic control is evidenced by the negative
impact on patient well-being and healthcare
resource use in Spain that result from even non-
severe events.
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